ERBB2 and breast carcinoma: The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) has issued several updates regarding the interpretation of IHC and ISH to standardize the evaluation process for Her2 in breast cancer [1,2,3,4].